Digital spatial profiling for identification of prognostic genes and molecular subgroups in pleural mesothelioma.
Abstract
8084 Background: Pleural mesothelioma (PM) is an aggressive malignancy that harbors significant inter- and intra-tumoral heterogeneity. Spatial transcriptomics enables the dissection of the tumor's molecular architecture by facilitating compartment-specific gene expression profiling. We performed high-resolution RNA-seq analysis of tumor (Tm) and stroma (St) compartments in PM samples to identify gene expression patterns and their association with clinical outcomes. Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from untreated PM patients (pts) across three institutions were analyzed using the NanoString GeoMx Digital Spatial Profiling (DSP) platform. Regions of interest (ROIs) were selected based on histopathological features and fluorescently labeled antibodies for tumor and stromal areas. RNA expression of >1800 genes from selected ROIs was analyzed using GeoMx Cancer Transcriptome Atlas (CTA). Differential gene expression was assessed utilizing R “limma” package. A cutoff of absolute fold change ≥1 and p-value <0.05, with the Benjamini-Hochberg false discovery rate method, was applied to identify significant differentially expressed genes (DEGs). Elastic Net regression optimized through cross-validation methods was employed to identify genes associated with overall survival (OS) outcomes. Data from the TCGA PanCancer Atlas was utilized for external validation. Results: A total of 72 pts, 80.3% male, median age of 71y (range: 44-94) were identified for the analysis. Among them, 87.5% (63/72) were epithelioid (Ep) and 12.5% (9/72) non-epithelioid (NEp). After quality control, RNA data was available from 71 and 67 pts in Tm and St compartments, respectively. Across 132 ROIs in the Tm compartment, we identified 4 significantly DEGs between NEp (upregulated COL5A2, THBS1 ; downregulated CLU, KRT19 ) and Ep subgroups. No DEG between Ep and NEp subgroups were identified in 115 ROIs from the St compartment. Unsupervised clustering identified four molecular subgroups with distinct gene expression in the Tm compartment, of which Cluster 1 showed significantly decreased OS (6.3m vs. 16.4m; HR 3.3, p =0.001). Elastic Net regression identified 31 genes predictive of OS (R² = 0.43, Harrell’s c-index = 0.87), including nine genes ( IFNGR2, FCER1G, MFGE8, CKLF, CBL, HLA-DRB3, HK1, PLAT, CD163 ) associated with worse prognosis. Tumors in Cluster 1 demonstrated higher expression of these genes. External validation using the TCGA cohort confirmed four genes IFNGR2 ( p = 0.02), CBL ( p = 0.01), HK1 ( p <0.001), PLAT ( p <0.001), as significantly associated with decreased OS in PM. Conclusions: Spatially resolved transcriptomic profiling suggests Tm-enriched regions as the primary drivers of PM subtype and aggressiveness, identifying nine genes and a molecular subgroup associated with poorer survival outcomes. Further validation and functional studies are warranted.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (20)
Mercedes Herrera
Hospital Universitario 12 de Octubre, Madrid, Spain
David Lora
Faculty of Statistics, Complutense University of Madrid, Madrid, Spain
Melina Peressini
Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain
Ramon Yarza
START Madrid, Madrid, Spain
Jose Maria Gracia
H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain
Álvaro C. Ucero
H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain
Magdalena Molero Abraham
Tumor Microenvironment and Immunotherapy Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Ana Belén Enguita
Department of Pathology. Hospital Universitario 12 de Octubre, Madrid, Spain
David Gómez-Sánchez
H12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital Universitario 12 de Octubre (i+12), Madrid, Spain
Vera Adradas Rodriguez
Tumor Microenvironment and Immunotherapy Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Esther Conde
Pathology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Research Institute Hospital 12 de Octubre (i+12), CIBERONC, Madrid, Spain
Nuria Carrizo
Department of Pathology, Hospital Universitario 12 de Octubre, Madrid, Spain
Igor Gomez-Randulfe
Roxana Reyes
Noemi Reguart
Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
Javier Baena
Helena Bote de Cabo
Hospital Universitario 12 de Octubre, Madrid, Spain
Santiago Ponce Aix
Hospital Universitario 12 de Octubre, Madrid, Spain
Luis G. Paz-Ares
Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
Jon Zugazagoitia
Department of Medical Oncology, 12 de Octubre Hospital, Madrid